When to Come Off Mounjaro: What the Guidance Actually Says

What NICE and the trial data say about continuing or stopping

The NICE appraisal of tirzepatide (TA1026, published December 2024) contains one explicit stopping rule: if a patient has not lost at least 5% of their body weight after six months at the highest dose they can tolerate, continuing treatment should be reviewed. That benchmark exists because tirzepatide is effective at producing clinically meaningful weight loss for most people who tolerate it well, so a lack of response at six months is a signal worth acting on, not one to wait out indefinitely.

What TA1026 does not include is a fixed treatment ceiling of one or two years. That matters because Mounjaro's situation differs from Wegovy's, where the NICE guidance for semaglutide restricts NHS use to a maximum of two years. The tirzepatide appraisal was written with the understanding that obesity is a chronic condition, and long-term treatment can be clinically appropriate. This is consistent with the SURMOUNT-1 trial evidence: among the roughly 2,500 adults studied over 72 weeks, participants who stopped tirzepatide at the end of the active phase regained a substantial portion of lost weight, which is why the question of when to stop should include a plan for what comes next.

If you want to understand how quickly Mounjaro typically begins working before this question becomes relevant, the page on how long Mounjaro takes to work covers the evidence in detail.

Reasons a prescriber might recommend stopping or stepping down

Outside the five-percent benchmark, several situations make stopping a reasonable clinical conversation. A person who has reached and stabilised at their target weight (and whose prescriber judges that lifestyle changes are sufficiently embedded) may be a candidate to taper off. The same applies if a weight-related condition that triggered eligibility has resolved or improved to the point where the risk-benefit balance of treatment has genuinely shifted.

Side effects are another reason. Persistent nausea, significant gastrointestinal disruption, or any serious concern flagged to a prescriber may prompt a pause or a step down in dose rather than an immediate full stop. A prescriber might also recommend stopping if a patient becomes pregnant, is planning to conceive, or is breastfeeding, because tirzepatide is not recommended in those circumstances. The NHS guidance on how to come off Mounjaro describes the process in practical terms, including why a gradual step-down is usually preferred over stopping without warning.

Financial or logistical reasons come up too, and a good prescriber will talk about them without judgment. If cost is part of your thinking, the Mounjaro price comparison page sets out what private treatment typically costs and what is included in a reputable service.

What the evidence says about stopping and weight regain

This is where the trial data is most instructive, and most honest. The SURMOUNT-1 findings, published in the New England Journal of Medicine, showed that participants who received tirzepatide regained a significant proportion of lost weight in the year following discontinuation compared with those who continued. This is not a failure of the medicine or the patient. It reflects the biological reality of obesity as a condition in which appetite-regulating hormones do not simply reset when treatment stops.

The practical implication is that coming off Mounjaro without a maintenance strategy in place puts the work of those months at greater risk. That strategy typically means sustained dietary changes, physical activity habits that can outlast the appetite suppression tirzepatide provides, and ideally a prescriber who checks in after stopping rather than simply closing the case. The page on coming off Mounjaro without regaining weight covers what the evidence and clinical guidance say about making the transition successfully.

It is worth being realistic: the pen sitting in the fridge door is not a permanent fixture for everyone, but ending treatment well takes the same clinical thought that starting it did. Expected timelines for significant weight loss can help set realistic expectations about where you should be in your progress before the stopping question becomes pressing.

How to have the conversation with your prescriber

The NHS guidance on weight-management injections, published by NHS England, is clear that decisions about continuing or stopping should involve your clinical team. If you are on a private service, that means a registered prescriber who knows your history, not a general checklist.

At nume, a real clinician reads your notes before every repeat is approved. No auto-renewals, no prescriptions issued on the basis of a previous decision alone. That makes each review a genuine checkpoint where the question of whether to continue is on the table, not assumed. If you have questions about where you are in treatment, or whether stopping might be right for you, our prescribers are available seven days a week for aftercare. The right time to raise it is at your next review, or sooner if something has changed.

Speak to our prescribers through your aftercare channel, or if you are not yet a patient, start a free consultation to have your situation assessed from the beginning.